In clinical practice, substitution therapy is used, which involves the intravenous administration of standard factor IX, obtained either from donor plasma or through recombination, once a week for bleeding or as prophylaxis and 2–3 times a week for severe hemophilia. This evidence concerns the gene F9 and hemophilia.